Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chemotherapy
Adjuvant anthracycline-based chemotherapy for early breast cancer evaluated
July 28th, 2005
Researchers examined adjuvant anthracycline-based chemotherapy for early breast cancer. "The rationale to justify the use of anthracyclines as adjuvant therapy for breast cancer is their proven superiority over CMF. Indeed, this has been demonstrated by a number of randomized clinical trials and recently confirmed by the Oxford meta-analysis," scientists in Scotland reported. "Nevertheless, the absolute benefit is modest (on average 4%), and with the cost of increased toxicity. Interestingly, many individual trials were unable to confirm the role of anthracyclines in early breast cancer, though most of these were either under-powered to show such...
Source: Women's Health Weekly (2005-07-28)
|
